Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5975)	11/18/1998 4:10:00 PM
From: Vector1	Read Replies (1) \| Respond to of 9719

Peter, This is highly significant. 60,000 SNPs is a large enough number to create a SNP map and would be valuable to big pharma. How in the word did they get there first. Genset has been working on this for 2 years and rumor isthey are not even at 50,000 yet. INCY by all accounts is not there yet. V1

To: Biomaven who wrote (5975)	11/18/1998 4:35:00 PM
From: Harold Engstrom	Respond to of 9719

Peter, in the For What Its Worth department... was at the Biogen annual meeting and Curagen was a subject of discussion because of the investment the company has made in Curagen. Not surprisingly, executives and scientists are apparently very high on Curagen - their science was supposed to be excellent and their scientists apparently very easy to collaborate with.